Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male Subjects

Phase I Comparison of Pharmacokinetics, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in a Randomized, Double-blind, Parallel Controlled, Single-dose Study in Healthy Chinese Male Subjects

A phase 1, randomized, double-blind, parallel group, single-dose study to compare the pharmacokinetics, safety and immunogenicity of two formulations of Omalizumab (Process-Changed CMAB007 and Xolair) in healthy subjects.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteers (HV)
• Intervention / Treatment: Biological: Process-Changed CMAB007; Biological: Xolair (omalizumab)

Detailed Description

This is a randomized, double-blind, parallel-controlled, single-dose phase I clinical study in healthy Chinese male subjects. A total of 114 subjects were planned to be enrolled and randomly assigned to the test group or the control group in a 1:1 ratio. Subjects in both groups received a single subcutaneous injection of Process-Changed CMAB007 or Xolair(Omalizumab) 150 mg, respectively. Subjects in both groups were observed for 106 days after administration to evaluate similarities in PK, safety, and immunogenicity.

• Study Type: Interventional
• Enrollment (Actual): 114
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Shanghai, China
    • Shanghai Xuhui Central Hospital, Shanghai

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Healthy male volunteers, age ranged 18 to 45 years (both inclusive) when sign the informed consent form.
2. Subjects with body weight of ≥50 kg and ≤ 75 kg and BMI ≥20.0 and ≤ 26.0 kg/m2 (both inclusive).
3. Subjects have the ability to understand the full characteristics and objectives of the study, including the possible risks and side effects of the study; moreover, subjects can communicate well with researchers and complete the research according to the regulations.
4. Subjects must be informed consent of the study and voluntarily sign informed consent form (name and time) prior to the study.

Exclusion Criteria:

1. After medical examination (vital signs, physical examination, electrocardiogram, positive chest X-radiography, abdominal B-ultrasound, and various laboratory examinations including blood routine, urine routine, blood biochemistry and total IgE, etc.), any examination item was judged abnormal by the investigator and had clinical significance.
2. Subjects with a history of clinically significant drug or food allergies, a history of specific allergic diseases (e.g., asthma, urticaria, eczematous dermatitis), allergic rhinitis, or a known allergy to any component of the investigational drug or latex (the syringe needle cover contains latex) as determined by the investigator..
3. Those who have a history of serious diseases including but not limited to cardiovascular system, respiratory system, digestive system, urogenital system, endocrine system, immune system, mental or nervous system (eg, epilepsy, etc), or currently have any of the above diseases or active infected diseases, or any other disease or medical condition that may interfere with the results of the trial, such as hereditary bleeding tendency, coagulation disorders or history of blood clots or bleeding.
4. History of malignant neoplasms within the last 5 years (other than completely resected basal cell or squamous cell carcinoma of the skin in situ).
5. Any one of HBV surface antigen, HIV antibody, HCV antibody and treponema pallidum antibody is positive.
6. Anti-nuclear antibody is positive.
7. Fecal parasite test is positive.
8. Those who smoke more than 10 cigarettes per day on average in the 6 months before screening.
9. Alcoholics or regular drinkers within 3 months before the test, i.e. those who drink more than 14 unites of alcohol per week (14 bottles of 360 ml beer or 45 ml spirits with 40% alcohol or 150 ml wine), or whose alcohol breath test is positive.
10. Drug abusers, or use of soft drugs within 3 months prior to screening or hard drugs within 1 year prior the trial, or excessive daily consumption of tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup =250mL) in the 3 months prior to screening, or positive urine drug screening.
11. Surgery within 4 weeks prior to screening; Or plan to have surgery during the study period.
12. Use of any prescription drug, over-the-counter drug or health product or vaccine within 4 weeks prior to screening, or who plan to receive live vaccine during the study period, or prior use of drug within 5 half-lives, whichever is longer.
13. Subjects who have donated blood (including whole blood or component blood) or experienced blood loss of more than 400 mL within 3 months prior to screening, or have received a blood transfusion; or who have donated blood (including component blood) or experienced blood loss of more than 200 mL within 1 month prior to screening; or who plan to donate blood during the study period..
14. Those who have been enrolled in other clinical studies or less than 3 months since the end of the most recent clinical study.
15. Subjects and their partners were not willing to use medically approved contraceptive methods within 6 months of study administration, or partners plan to become pregnant, or subjects plan to donate sperm.
16. Use of anti-IgE mab within 12 months, or any biological agent within 3 months prior to screening.
17. The investigator judges the subject inappropriate to be included in this study or other reasons not eligible to complete the study.
18. Employees or related personnel of the research unit, sponsor or contract research organization.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Xolair; 150 mg Subcutaneous injection	Biological: Xolair (omalizumab); for subcutaneous injection only
Experimental: Process-Changed CMAB007; 150 mg Subcutaneous injection	Biological: Process-Changed CMAB007; for subcutaneous injection only

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time	Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time After the Single injection of Omalizumab	up to 2520 hours
Maximum Concentration of Omalizumab	Maximum Concentration After the Single Injection of Omalizumab	up to 2520 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 2520 Hours	Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 2520 Hours After the Single Injection of Omalizumab	up to 2520 hours
Time to Maximum Concentration of Omalizumab	Time to Maximum Concentration of Omalizumab after the Single Injection of Omalizumab	up to 2520 hours
Half time	Half-time after the Single Injection of Omalizumab	up to 2520 hours
Terminal elimination rate constant (λz)	Terminal elimination rate constant (λz) after the Single Injection of Omalizumab	up to 2520 hours
Apparent total body clearance (CL/F)	Apparent total body clearance (CL/F) after the Single Injection of Omalizumab	up to 2520 hours
Apparent total distribution (Vd/F)	Apparent total distribution (Vd/F) after the Single Injection of Omalizumab	up to 2520 hours
anti-drug antibodies (ADA)	ADA Positive Rate after the Single Injection of Omalizumab	up to 2520 hours
Neutralization antibodies (Nab)	Neutralizing Antibody Positive Rate after the Single Injection of Omalizumab	up to 2520 hours
Percentage and Severity of Participants with Adverse Events	Total Frequency and Severity of Adverse Events/Serious Adverse Events Within the Whole Time of the Study	up to 2520 hours

Collaborators and Investigators

• Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd
• Investigators: Principal Investigator: Jingying Jia, Ph.D, Shanghai Xuhui Central Hospital

Study record dates

Study Major Dates

• Study Start (Actual): March 28, 2024
• Primary Completion (Actual): September 30, 2024
• Study Completion (Actual): December 2, 2024

Study Registration Dates

• First Submitted: November 17, 2025
• First Submitted That Met QC Criteria: November 17, 2025
• First Posted (Actual): November 24, 2025

Study Record Updates

• Last Update Posted (Actual): November 24, 2025
• Last Update Submitted That Met QC Criteria: November 17, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Amino Acids, Peptides, and Proteins; Proteins; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Serum Globulins; Globulins; Antibodies, Anti-Idiotypic; Omalizumab
• Other Study ID Numbers: CMAB007-004

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No